Europe Digital Diabetes Management Market

The Europe digital diabetes management market is projected to reach USD 12.53 billion by 2031 from USD 7.78 billion in 2026 at a CAGR of 10.0% during the forecast period.

The increased prevalence of diabetes continues in Europe owing to its aging population, sedentary lifestyles, obesity, and changing diets. Most type 2 diabetes cases become a long-term pressure on the public healthcare systems. The rising costs incurred by managing complications such as those of the cardiovascular system, nephropathy, and neuropathy incited policymakers and payers to seek remedies for cost-effective management of the disease. The digital diabetes management platform facilitates early intervention, continuous monitoring, and improved adherence to lifestyle, all of which reduce hospitalization and complication-related costs. This strong epidemiologic and economic burden creates a sustained demand base for scalable digital diabetes solutions across Europe.

In April 2021, Medtronic announced the European launch of an extended infusion set with a wear time of up to seven days to help reduce diabetes management burden.

In February 2023, Ascensia Diabetes Care (Switzerland) collaborated with SNAQ (Switzerland). This collaboration aims to integrate Ascensia and SNAQ technologies to empower people with diabetes (PWDs) to make informed, real-time decisions, thereby improving overall diabetes management outcomes.

In this report, the Europe digital diabetes market has been segmented based on product & service, device type, end user, and country.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in this market include Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Tandem Diabetes Care (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), Pendiq GmbH (Germany), One Drop (US), Decide Clinical Software GmbH (Austria), and BeatO (India).

Dexcom, Inc. (us)

Dexcom is in the top tier of the Europe digital diabetes management market. Its product lineup includes CGM systems such as Dexcom G7 and iCGM System, Dexcom G6 Continuous Glucose Monitoring (CGM) System, Dexcom G5 Mobile CGM System, and Dexcom One. The company operates 242 manufacturing and distribution facilities globally. Dexcom's strategy for increasing its share of digital diabetes management is through alliances, contracts, and acquisitions. In recent years, Dexcom has been forming partnerships to combine its CGM system with various insulin pumps. With a growing emphasis on an increased global footprint, the company provides itself with much richer resources for production and servicing of its customer base.

Medtronic (Ireland)

Medtronic holds a strong position in the Europe digital diabetes management market, supported by its comprehensive portfolio spanning insulin pumps, continuous glucose monitoring (CGM) systems, smart glucose meters, mobile applications, and integrated data management software. The company’s MiniMed 780G and MiniMed 670G automated insulin delivery systems, Guardian Connect CGM, CareLink Diabetes Personal software, and StartRight patient support programs form the core of its digital diabetes ecosystem in Europe. With manufacturing and operational headquarters in Ireland and a well-established commercial presence across key European countries, Medtronic benefits from favorable regulatory access and reimbursement pathways. Continuous product innovation, system automation, and strategic partnerships with healthcare providers enable the company to strengthen clinical adoption and maintain leadership in Europe’s digital diabetes management landscape.

Abott (us)

Abott provides CGM systems, smart insulin pens, smart insulin pumps, smart insulin patches, and data management software. It also offers connected glucose meters. Under the leading brand of Freestyle Libre, It offers a comprehensive range of digital CGM devices for managing diabetes, along with software platforms that have gained much popularity among end users in countries across the globe. The company primarily focuses on product launches, alliances, and collaborations. In October 2022, it released a new CGM system called FreeStyle Libre 3-beta, which has significantly increased revenue.

Market Ranking

The Europe digital diabetes management market is highly consolidated, with prominent players accounting for over 70% of the total market share in 2025. Some of the players dominating the market include Medtronic (Ireland), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), and Ascensia Diabetes Care Holdings AG (Switzerland).

The Europe digital diabetes management market is marked by the strong presence of multinational medical device and digital health companies, supported by emerging regional digital therapeutics and software providers. Market players are increasingly focusing on cost-effective connected glucose monitoring devices, mobile applications, and cloud-based platforms to align with public healthcare budgets. Rising diabetes prevalence, improving reimbursement for CGM and remote monitoring, and growing adoption of telemedicine are encouraging companies to strengthen partnerships with hospitals, payers, and national health systems across Europe.

Related Reports:

Europe Digital Diabetes Management Market by Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Self/Home Healthcare) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com